Neisseria gonorrhoeae (NG) is a major causative pathogen of STI and is one of the most commonly detected pathogens due to its high infection rate. NG can spread easily, but it is often asymptomatic and can be left untreated. When left untreated, NG can cause serious health problems in women including ectopic pregnancy and infertility. Treatment of gonorrhea has become more complex with increasing resistance to fluoroquinolone drugs and the need for monitoring and controlling other options like macrolide or cephalosporin resistance.

Novaplex™ NG & DR Assay* is a multiplex real-time PCR assay that can accurately detect NG and drug resistance (Azithromycin, Ciprofloxacin) with a single test. It can also be used with Seegene’s other STI assays to provide informative STI testing results.

Mycoplasma genitalium (MG) has been recognized for potentially serious health complications including urethritis in men, and cervicitis, PID, preterm birth, and spontaneous abortion in women. Primary treatment of MG is the macrolide antibiotic azithromycin. For azithromycin-resistant MG, the fluoroquinolone antibiotic moxifloxacin can be used as the second-line treatment. For M. genitalium, drug resistance is an emerging problem similar to other STIs. Some strains exhibit resistance to both lines of treatment with resistance easily acquired through single point mutation in the DNA.

Seegene offers two drug-resistance detection assays for M. genitalium. Both assays detect single DNA mutations that cause resistance as well as MG infection itself.  Both assays use exogenous IC for urine and endogenous IC for others. The Novaplex™ MG & AziR Assay* and the Novaplex™ MG & MoxiR Assay* are designed to be run together with the Novaplex™ CT/NG/MG/TV Assay*.